These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 25651450)
1. Influence of anti-VEGF about cardiovascular biomarkers in age related macular degeneration. Manresa N; Mulero J; Losada M; Zafrilla P J Nutr Health Aging; 2015 Feb; 19(2):228-31. PubMed ID: 25651450 [TBL] [Abstract][Full Text] [Related]
4. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630 [TBL] [Abstract][Full Text] [Related]
5. EFFECT OF PEGAPTANIB AND RANIBIZUMAB ON PLASMA AND VITREOUS HOMOCYSTEINE IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Manresa N; Mulero J; Losada M; Zafrilla P Retina; 2015 Sep; 35(9):1765-71. PubMed ID: 25923955 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. Jeganathan VS; Verma N Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163 [TBL] [Abstract][Full Text] [Related]
8. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Day S; Acquah K; Mruthyunjaya P; Grossman DS; Lee PP; Sloan FA Am J Ophthalmol; 2011 Aug; 152(2):266-72. PubMed ID: 21664593 [TBL] [Abstract][Full Text] [Related]
9. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124 [TBL] [Abstract][Full Text] [Related]
10. [Monotherapy of exudative age-related macular degeneration with ranibizumab in patients at cardiovascular risk. Advantages of ranibizumab compared to a combination with pegaptanib]. Matthé E; Sandner D Ophthalmologe; 2011 Apr; 108(4):337-41. PubMed ID: 21181168 [TBL] [Abstract][Full Text] [Related]
11. [Wet form age-related macular degeneration two years treatment results using anti VEGF drugs]. Studnička J; Rencová E; Dusová J; Marák J; Burova M; Rozsíval P; Jarkovský J; Kandrnal V Cesk Slov Oftalmol; 2013 Aug; 69(3):96-101. PubMed ID: 24437955 [TBL] [Abstract][Full Text] [Related]
12. Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration. Semeraro F; Morescalchi F; Parmeggiani F; Arcidiacono B; Costagliola C Curr Vasc Pharmacol; 2011 Sep; 9(5):629-46. PubMed ID: 21470108 [TBL] [Abstract][Full Text] [Related]
14. Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal? Neri P; Mariotti C; Arapi I; Bambini E; Giovannini A Curr Med Res Opin; 2012 Mar; 28(3):395-400. PubMed ID: 22283373 [TBL] [Abstract][Full Text] [Related]